You've probably seen or heard ads for the brain training app Lumosity boasting that its games were designed by neuroscientists and were scientifically proven to help stave off Alzheimer's as well as improve real-world cognitive performance. Well, you won't be seeing those ads anymore. Lumosity maker Lumos Labs are now banned from making such claims as the result of a multimillion-dollar settlement with the Federal Trade Commission, the agency said today.

Launched in 2007, Lumosity offers over 50 different games designed to improve cognitive skills such as attention and memory. You can play some of the games for free; Lumos Labs sells access to the full suite of games, which can be played either on the web or via mobile apps, for $5 to $15 per month. Although Lumosity wasn't the first to offer "brain training" games to the public, it became the most famous thanks in large part to an aggressive advertising campaign touting its effectiveness at everything from boosting grades to improving athletic performance. The problem is, according to the FTC, those claims aren't actually backed up by science.

The company failed to disclose that many of its testimonials were solicited as part of a contest that offered winners prizes such as iPads or a free trip to San Francisco.

The FTC's complaint alleges that Lumos Ads misled customers with false or deceptive advertising, and that the company had failed to disclose that many of its testimonials had been solicited as part of a contest that offered winners prizes such as iPads, lifetime subscriptions to Lumosity, or a free trip to San Francisco.

Lumos Labs and its employees and representatives are now banned from making claims that Lumosity and related products improve academic or athletic performance, stave off dementia or other cognitive disorders, or treat other conditions such as attention deficit disorder (ADHD) or post-traumatic stress disorder (PTSD) until the company can back those claims with "competent and reliable scientific evidence."

The order defines competent and reliable scientific evidence as clinical testing conducted by qualified researchers with adequate controls "considered in light of the entire body of relevant and reliable scientific evidence."

As part of the settlement, Lumos Labs agreed to pay the FTC $50 million but a district court suspended all but $2 million of that amount because the company couldn’t actually afford it1. (Lumos Labs did not respond to WIRED's request for comment.) The company must also notify all current Lumosity subscribers of the FTC's order and provide them with a link to an easy way to unsubscribe from the service.

1Correction 1/6/2016 2:10 PM EST: An earlier version of this story stated that the FTC suspended all but $2 million of the settlement amount. A district court actually suspended it.